Catalog No.
Product Name
Application
Product Information
Citations
-
SCD Inhibitor
Cbz-D-Trp-OH is a competitive inhibitor of stearoyl-CoA desaturase (SCD), demonstrating an IC50 of 86 μM and a Ki value of 71 μM. This compound modulates lipid biosynthesis and is instrumental in studying lipid metabolism and related metabolic disorders. Its use is pertinent in research focused on understanding the role of SCD in obesity, diabetes, and cardiovascular diseases. -
SCD1 Inhibitor
SCD1 inhibitor-5 is a selective inhibitor of stearoyl-CoA desaturase-1 (SCD1), exhibiting IC50 values of 0.13 μM in H2122 cells and 31 μM in H1819 cells. This compound effectively reduces SCD1 activity, making it a valuable tool in cancer research. Its inhibition of lipid metabolism pathways can provide insights into tumor growth and proliferation mechanisms. -
STS Inhibitor
Estrone O-sulfamate is a potent inhibitor of steroid sulfatase (STS), a key enzyme involved in steroid hormone metabolism. It demonstrates significant inhibitory activity with IC50 values of 18 nM in placental microsomes and 0.83 nM in MCF-7 cells. This compound is valuable for research focused on cancer, as it helps elucidate the role of STS in tumorigenesis and hormone-driven malignancies. -
Steroid Sulfatase Inhibitor
Estradiol 3-sulfamate is a potent steroid sulfatase inhibitor, effectively targeting estrone sulfatase with an IC50 value of 251 nM and a Ki of 133 nM. This compound is recognized for its long-acting and orally active properties, making it a valuable reagent for research applications focused on hormone metabolism and endocrine signaling. Its ability to modulate sulfated steroid levels supports investigations into various biological processes, including cancer research and reproductive health studies. -
Steroid Sulfatase Inhibitor
KW-2581 is a selective steroid sulfatase (STS) inhibitor, exhibiting an IC50 of 4 nM. This compound effectively inhibits STS activity in ZR-75-1 cells with an IC50 of 13 nM, demonstrating significant impairment of E1S-stimulated cell growth at an IC50 of 0.18 nM. KW-2581 has shown the ability to inhibit sulfated estrogen-dependent proliferation of breast cancer cells both in vitro and in vivo, leading to tumor regression in E1S-induced models. This reagent is suitable for studies focused on hormone receptor-positive breast cancer and the role of steroid sulfatase in tumor biology. -
STS Inhibitor/ERα Modulator
SR-16157 is a dual-action steroid sulfatase (STS) inhibitor and selective estrogen receptor alpha (ERα) modulator, with an IC50 of 0.1 µM. This compound displays potent STS inhibitory and anti-estrogenic effects in breast cancer cells, making it a valuable tool for understanding the role of estrogen signaling in cancer progression. SR-16157 is applicable in breast cancer research, particularly in studies exploring therapeutic strategies targeting estrogen metabolism and receptor modulation. -
Steroid Sulfatase Inhibitor
Steroid sulfatase-IN-10 is a potent inhibitor of steroid sulfatase, exhibiting an IC50 range of 0.03-0.27 µM. This compound is valuable for investigating its role in various inflammatory conditions, including rheumatoid arthritis, type 1 and type 2 diabetes, and systemic lupus erythematosus. Its selective inhibition of steroid sulfatase makes it a useful tool in exploring therapeutic avenues for these diseases. -
Steroid sulfatase/17β-HSD1 Inhibitor
Steroid sulfatase/17β-HSD1-IN-3 is a potent dual inhibitor targeting steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β HSD1). It irreversibly inhibits human STS activity with an IC50 of 27 nM, demonstrating significant efficacy. This compound is suitable for research focused on endometriosis and other estrogen-dependent diseases, facilitating the exploration of therapeutic strategies in these areas. -
STS Inhibitor
Steroid Sulfatase-IN-2 is a potent steroid sulfatase (STS) inhibitor, exhibiting an IC50 value of 109.5 nM. This compound enables research into hormone-dependent cancers, particularly those driven by estrogen, such as breast and endometrial cancer. Its role as an STS inhibitor makes it a valuable tool for understanding the molecular mechanisms underlying these cancer types and exploring potential therapeutic strategies. -
STS Inhibitor
Steroid sulfatase-IN-8 is a potent steroid sulfatase (STS) inhibitor, demonstrating a pharmacological IC50 of 1 nM in PM models and 0.025 nM in JEG-3 cells. This compound effectively interferes with steroid metabolism, making it a valuable tool for investigating steroid-related pathways. Its application extends to studies on hormone-dependent cancers and other conditions linked to altered steroid levels. -
Steroid Sulfatase Inhibitor
DU-14 is a potent inhibitor of steroid sulfatase, exhibiting an IC50 of 55.8 nM. It effectively reduces MCF-7 cell proliferation, with an IC50 value of 38.7 nM. Additionally, DU-14 demonstrates neuroprotective properties against neurotoxic amyloid-beta (Aβ), indicating its potential to up-regulate endogenous dehydroepiandrosterone sulfate (DHEAS) and alleviate Aβ-induced deficits in spatial memory and synaptic plasticity. This compound is valuable for research in cancer biology and neurodegenerative diseases. -
STS Inhibitor
Steroid sulfatase-IN-4 is an irreversible inhibitor of steroid sulfatase (STS), exhibiting an IC50 of 25 nM against human STS. This compound is primarily utilized in research focused on endometriosis, offering potential insights into the role of STS in disease progression and therapeutic interventions. Its selective inhibition of STS facilitates the exploration of hormonal pathways involved in reproductive health. -
STS Inhibitor
Steroid sulfatase-IN-3 is a potent inhibitor of steroid sulfatase (STS) with an IC50 value of 25.8 nM. This compound exhibits significant antiproliferative activity against T-47D estrogen-dependent breast cancer cells, demonstrating an IC50 of 1.04 µM. Steroid sulfatase-IN-3 is primarily utilized in cancer research to explore the role of STS in hormone-dependent tumor progression and treatment resistance. -
Steroid Sulfatase Inhibitor
Steroid sulfatase-IN-1 is a highly effective inhibitor of steroid sulfatase, exhibiting an IC50 value of 1.71 nM. This compound demonstrates significant antitumor activity in vivo, indicating its potential utility in cancer research. Steroid sulfatase-IN-1 is particularly relevant for studies focused on breast cancer, providing insights into mechanisms of disease and potential therapeutic approaches. -
Steroid sulfatase/17β-HSD1 Inhibitor
Steroid sulfatase/17β-HSD1-IN-1 is a potent inhibitor of steroid sulfatase and 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), exhibiting an IC50 value of 28 nM for human steroid sulfatase in cellular assays. This compound is valuable for investigating estrogen-dependent diseases, making it an important tool for research in hormone-related therapeutic areas. Its specificity and potency support studies aiming to elucidate the role of these enzymes in disease mechanisms. -
Steroid sulfatase/17β-HSD1 Inhibitor
Steroid sulfatase/17β-HSD1-IN-4 is a potent dual inhibitor of steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β HSD1). It irreversibly inhibits hSTS activity, demonstrating an IC50 value of 63 nM. This compound is valuable for studying endometriosis and other estrogen-dependent diseases, providing insights into the role of steroid metabolism in these conditions. -
Steroid Sulfatase Inhibitor
Steroid sulfatase-IN-11 is a potent inhibitor of steroid sulfatase, an enzyme that hydrolyzes steroid sulfates. By effectively reducing steroid sulfatase activity, this compound is instrumental in the study of hormone-dependent cancers. Its application in research provides valuable insights into the role of steroid metabolism in cancer progression and therapeutic resistance. -
Succinate Dehydrogenase Inhibitor
Flubeneteram is an inhibitor of succinate dehydrogenase, exhibiting an IC50 value of 0.0484 μM. This compound effectively disrupts the activity of succinate dehydrogenase, contributing to its biological activity. Flubeneteram has demonstrated protective effects against fungal pathogens such as Rhizoctonia solani and Sphaerotheca fuliginea in preclinical studies. It is a valuable reagent for research focused on fungal infection mechanisms and potential therapeutic strategies. -
Herbicide
Herbicidal agent 6 (D15) is a potent inhibitor of transketolase (TKL), specifically designed for herbicidal applications. This compound demonstrates significant herbicidal activity, effectively disrupting the metabolic pathways in target plants. Its mechanism of action positions it as a valuable tool for research in agricultural biotechnology and plant science, focusing on crop protection and weed management strategies. -
TrxR Fluorescent Probe
TRFS-green is a selective fluorescent probe designed for the imaging of thioredoxin reductase (TrxR) in living cells. Upon activation by TrxR, TRFS-green exhibits a significant shift in its maximum absorbance from approximately 373 nm to around 440 nm. This property enables enhanced visualization of selenoprotein activity, making TRFS-green a valuable tool in cellular and biochemical research focused on redox biology and oxidative stress. -
TrxR Inhibitor
Ethaselen is a selective thioredoxin reductase (TrxR) inhibitor known for its potent inhibitory action, with IC50 values of 0.5 μM for wild-type human TrxR1 and 0.35 μM for rat TrxR1. This organoselenium compound specifically targets the unique selenocysteine-cysteine redox pair in the C-terminal active site of mammalian TrxR1. Ethaselen demonstrates significant antitumor activity, particularly against non-small cell lung cancer (NSCLC), making it a promising candidate for cancer research applications focused on apoptosis and redox regulation. -
TrxR1 Inhibitor
DVD-445 is a potent peptidomimetic inhibitor of thioredoxin reductase 1 (TrxR1), exhibiting an IC50 value of 0.60 μM against rat TrxR1. This compound demonstrates significant anticancer activity, making it a valuable tool for research applications focused on cancer biology and oxidative stress mechanisms. Its ability to interact covalently with TrxR1 positions DVD-445 as an important reagent for exploring therapeutic strategies targeting oxidative stress in cancer cells. -
TrxR Inhibitor
TrxR-IN-2 is a selective inhibitor of thioredoxin reductase (TrxR), a critical enzyme involved in redox regulation. This compound demonstrates significant inhibitory activity in various cancer models, particularly in drug-resistant hepatocellular carcinoma. TrxR-IN-2 is suitable for research applications focused on understanding TrxR's role in cancer biology and exploring potential therapeutic strategies against aggressive tumor types. -
Trx/TrxR System Inhibitor
PMX464 is a thiol-reactive quinol that acts as an inhibitor of the thioredoxin-thioredoxin reductase (Trx/TrxR) system. This compound has been shown to inhibit NF-κB-mediated pro-inflammatory activation in human type II alveolar epithelial cells, making it a valuable tool for research focused on inflammation and oxidative stress. PMX464 is particularly useful in studies examining the role of redox signaling in various pathophysiological conditions. -
Two-Photon Fluorescent TrxR Probe
TP-TRFS is a selective two-photon fluorescent probe designed to target thioredoxin reductase (TrxR). Its primary mechanism involves the detection of TrxR activity through fluorescence, making it a valuable tool for studying redox biology. This probe is particularly useful for research applications involving oxidative stress, cellular signaling, and cancer biology, enabling real-time monitoring of TrxR in live cells. -
TrxR Inhibitor
TrxR-IN-3 is a potent inhibitor of thioredoxin reductase (TrxR), exhibiting significant antiproliferative activity against various human cancer cell lines, particularly breast cancer cells. This compound enhances reactive oxygen species (ROS) levels, leading to apoptosis through the modulation of apoptosis-related proteins. Additionally, TrxR-IN-3 promotes autophagy by increasing the expression of LC3-II and Beclin-1 while reducing levels of LC3-I and p62, facilitating the formation of autophagosomes and autolysosomes. This makes TrxR-IN-3 a valuable tool for studying the mechanisms of cancer cell death and autophagy. -
TrxR1 Inhibitor
TrxR1-IN-1 is a selective inhibitor of thioredoxin reductase 1 (TrxR1), exhibiting an IC50 of 8.8 μM. This compound demonstrates significant anticancer activity, achieving IC50 values of 1.5 μM in MCF-7 cells, 1.7 μM in HeLa cells, 2.4 μM in BGC-823 cells, 2.8 μM in SW-480 cells, and 2.1 μM in A549 cells. Additionally, TrxR1-IN-1 possesses antioxidant properties and effectively scavenges DPPH radicals, making it a valuable tool for research in cancer biology and oxidative stress studies. -
TrxR Inhibitor
TrxR-IN-4 is a potent inhibitor of thioredoxin reductase (TrxR), demonstrating significant biological activity by inducing apoptosis in HepG2 cells via the activation of endoplasmic reticulum stress (ERS). This compound also exhibits protective effects against CCl4-induced liver damage in vivo, achieved through the down-regulation of TrxR expression and inflammatory responses. TrxR-IN-4 is a valuable tool for researching the modulation of oxidative stress and cancer therapies. -
TrxR Inhibitor
CPUL1 is a selective inhibitor of thioredoxin reductase (TrxR), demonstrating significant anti-proliferative and anti-metastatic effects in A549 lung cancer cells. It modulates epithelial-mesenchymal transition (EMT) through the induction of reactive oxygen species (ROS) and activation of ERK/JNK signaling pathways resulting from the inhibition of TrxR1 enzyme activity. CPUL1 exhibits enhanced efficacy when used in combination with α-Lipoic Acid or Dithiodipropionic acid, making it a valuable tool for cancer research and therapeutic strategies. -
Tyrosinase Inhibitor
Methyl rosmarinate is a noncompetitive inhibitor of tyrosinase, effectively isolated from Rabdosia serra, with an IC50 value of 0.28 mM for mushroom tyrosinase. Additionally, it demonstrates inhibitory activity against α-glucosidase. This compound is valuable for research in pigmentation, skin disorders, and carbohydrate metabolism. -
PPO Inhibitor
2,3-Diaminopropionic acid hydrochloride acts as an inhibitor of polyphenol oxidase (PPO), an enzyme involved in the browning reaction of fruits and vegetables. This compound serves as a key precursor for the synthesis of antibiotics and the siderophore staphyloferrin B. Its ability to modulate PPO activity makes it valuable for research in enzymology and agriculture, particularly in studies aimed at controlling oxidative processes in various biological systems. -
XO Inhibitor
Procyanidin B2 3′-O-gallate is a potent inhibitor of xanthine oxidase (XO), exhibiting an IC50 of 24.24 μM and a Ki value of 6.16 μM. Its notable antioxidant activity allows for the reduction of UV-induced α-tocopheroxyl formation. This compound is suitable for research related to hyperuricemia and gout, providing a valuable tool for investigating therapeutic strategies in these conditions. -
DAAO Inhibitor
Luvadaxistat is a highly selective and potent inhibitor of D-amino acid oxidase (DAAO), demonstrating an IC50 value of 14 nM in the inhibition of oxidative deamination of D-serine. This compound significantly elevates D-serine concentrations in various biological matrices, including the rodent brain, plasma, and cerebrospinal fluid. Luvadaxistat holds promise as a valuable tool for research into schizophrenia and related neurobiological disorders. -
HDX Inhibitor
2-Methylacetophenone is a potent xanthine dehydrogenase (XDH) inhibitor that competently interacts with the XDH active site, effectively preventing the conversion of xanthine to uric acid. This compound is instrumental in research applications focused on hyperuricemia and conditions related to elevated uric acid levels. Its use can deepen the understanding of purine metabolism and contribute to the development of therapeutic strategies. -
Xanthine Oxidase Inhibitor
Tigulixostat is a selective xanthine oxidase inhibitor with potent activity, demonstrating IC50 values of 0.003 µM in bovine milk and 0.073 µM in rat plasma. This compound effectively lowers serum uric acid levels and is utilized in research focusing on gout and hyperuricemia. Its oral bioavailability and targeted mechanism make it a valuable tool in studying these conditions. -
Urate Oxidase
Rasburicase is a recombinant urate oxidase that catalyzes the oxidation of uric acid to allantoin, a more soluble compound. This mechanism effectively lowers blood uric acid levels, alleviates inflammation, and mitigates kidney damage associated with uric acid crystallization. Rasburicase is utilized in research related to severe hyperuricemia, particularly in conditions such as tumor lysis syndrome (TLS) and refractory gout. Its capacity to reduce uric acid levels makes it a valuable tool in studying the pathophysiology of related disorders. -
XOD Inhibitor
7,8,3′,4′-Tetrahydroxyflavone is a potent inhibitor of xanthine oxidase (XOD) with an IC50 value of 10.488 µM. This compound demonstrates significant inhibitory activity, making it a valuable tool for studies related to oxidative stress and purine metabolism. Research applications include investigating its potential therapeutic effects in conditions associated with hyperuricemia and gout. -
Xanthine Oxidase Inhibitor
8-Azaadenine is a potent inhibitor of xanthine oxidase, exhibiting an IC50 value of 0.54 μM and a Ki of 0.66 μM. This compound can be synthesized through the metabolism of 8-Azaadenosine and is capable of integrating into polynucleotide chains alongside 8-Azaguanine, thereby influencing purine metabolism. 8-Azaadenine serves as a valuable tool in cancer research, enabling investigations into therapeutic strategies targeting purine biosynthesis pathways. -
DAO Inhibitor
DAO-IN-1 is a potent inhibitor of D-amino acid oxidase (DAO), exhibiting an IC50 value of 269 nM. By inhibiting DAO, it effectively modulates D-serine levels, a crucial co-agonist of NMDA receptors. This compound is valuable for research investigating the roles of D-serine and NMDA receptor modulation in various neurological disorders. -
XO Inhibitor
Myricetin 3-O-galactoside is a potent xanthine oxidase (XO) inhibitor known for its antioxidant properties. It effectively reduces lipid peroxidation, exhibiting an IC50 value of 160 μg/mL. This compound is valuable for research applications focused on oxidative stress and related pathologies, providing insight into therapeutic approaches targeting reactive oxygen species. -
Xanthine Oxidase Inhibitor
O-Desisobutyl-O-n-propyl Febuxostat is an xanthine oxidase inhibitor that plays a crucial role in the modulation of uric acid levels. Its primary mechanism involves the inhibition of xanthine oxidase activity, which can be beneficial in the treatment of gout and hyperuricemia. This compound is valuable for research applications focused on purine metabolism, oxidative stress, and related metabolic disorders. Scientists can utilize it to explore therapeutic strategies targeting inflammatory pathways associated with elevated uric acid. -
XOR Inhibitor
Niraxostat is an orally active xanthine oxidoreductase (XOR) inhibitor. It is utilized in research focused on hyperuricemia and related pathologies where XOR plays a significant role in disease mechanisms. By inhibiting XOR, Niraxostat can help elucidate the biochemical pathways involved in uric acid metabolism and its associated conditions. -
Xanthine Oxidase Inhibitor
Azacosterol, a potent xanthine oxidase inhibitor, is known for its role as a DHCR24 inhibitor. This compound facilitates a series of biochemical reactions in cortical neurons, contributing to its significance in neurological research. Its unique mechanism positions it as a valuable tool in studies investigating oxidative stress and related pathways in various biological contexts. -
XO Inhibitor
Febuxostat sodium is a selective non-purine xanthine oxidase (XO) inhibitor, exhibiting a potent Ki value of 0.6 nM. It is primarily utilized in the investigation of hyperuricemia and gout due to its ability to effectively lower urate levels. This compound serves as a valuable tool for studying the biochemical pathways associated with purine metabolism and the therapeutic effects in gout-related conditions. -
XO Inhibitor
Xanthine oxidase-IN-7 is a potent xanthine oxidase (XO) inhibitor with an IC50 of 0.36 µM. It effectively lowers serum uric acid levels, making it a valuable tool for studying hyperuricemia and gout. This compound has significant potential in research applications focused on disorders related to uric acid metabolism. -
Xanthine Oxidoreductase Inhibitor
Xanthine oxidoreductase-IN-5 is a potent inhibitor of xanthine oxidoreductase (XOR), exhibiting an IC50 of 55 nM. This compound is employed in research focused on acute hyperuricemia, facilitating the investigation of uric acid metabolism and its associated disorders. Xanthine oxidoreductase-IN-5 serves as a valuable tool for exploring therapeutic strategies aimed at managing conditions related to elevated uric acid levels. -
XOR Inhibitor
Xanthine oxidoreductase-IN-2 is a potent inhibitor of xanthine oxidoreductase (XOR) with an IC50 value of 7.2 nM. This compound exhibits significant hypouricemic effects in murine models, making it a valuable tool for research into disorders related to uric acid metabolism. It is suitable for investigating the role of XOR in conditions such as gout and oxidative stress-related diseases. -
Anti-hyperuricemic Agent
NARS-3′ is a selective reversible inhibitor of xanthine oxidase, exhibiting an IC50 of 21.01 μM. This compound effectively competes with substrates to diminish uric acid production, demonstrating potential in mitigating renal damage in hyperuricemia models. NARS-3′ is suitable for research applications focused on hyperuricemia and related metabolic disorders. -
Antioxidant Agent
Antioxidant agent-13 is a potent antioxidant compound that targets DPPH and FRAP, exhibiting inhibitory activity with IC50 values of 80.33 μM and 85.69 μM, respectively. Additionally, this compound effectively inhibits lipoxygenase (LOX) and xanthine oxidase (XO) with IC50 values of 16.85 μM and 23.01 μM, respectively. Antioxidant agent-13 is valuable for research focused on oxidative stress and related pathological conditions, providing insights into potential therapeutic applications. -
Xanthine Oxidase Inhibitor
Xanthine oxidase-IN-19 is a potent inhibitor of xanthine oxidase (XO) with an IC50 of 0.2 μM. This compound effectively reduces serum uric acid levels in models of acute hyperuricemia, making it valuable for research into hyperuricemia-related conditions. Xanthine oxidase-IN-19 serves as a useful tool for studying the biochemical and physiological impacts of XO inhibition.
